DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the AARTI DRUGS LTD. (AARTIDRUGS) share price today?

AARTI DRUGS LTD. (AARTIDRUGS) is trading at ₹422.3 on the NSE, up 0.57% on the day. Source: DocStoX.

What is the PE ratio of AARTI DRUGS LTD.?

AARTI DRUGS LTD. has a price-to-earnings (PE) ratio of 19.8 in the Healthcare sector.

What is the market capitalisation of AARTI DRUGS LTD.?

AARTI DRUGS LTD. has a market capitalisation of approximately ₹3,849 crore.

AARTI DRUGS LTD.

AARTIDRUGS·NSE·Healthcare

₹422.30▲ +2.40 (+0.57%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹410.20

₹426.45

52W₹319

₹56442%

Open

₹422.00

High

₹426.45

Low

₹410.20

Prev Close

₹419.90

Volume

2.22L

VWAP

₹418.18

Snapshot

Key fundamentals

Market Cap

₹3,849 Cr

P/E Ratio

19.77Fair

P/B Ratio

2.26

EPS

₹21.36

Book Value

₹170.00

ROE

13.40%Average

ROCE

12.00%Decent

Dividend Yield

0.51%

Debt / Equity

0.37Moderate

Face Value

₹10.00

52W High

₹564.05

52W Low

₹318.95

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹197

▼ 53.4%downside

Trading at ₹422 — 53% above our estimate

BearFair valueBull

₹167₹197₹286

/100

Business quality — Watch the fundamentals

Growth 11Profitability 37Efficiency 10Valuation 79

Plain English

Our view

Revenue under pressure recently
Low debt relative to equity
Revenue has been shrinking

Strengths

Low debt relative to equity
Promoters hold a controlling stake

Risks

Revenue has been shrinking
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

13% ROE fading to 13% over ~3 yrs, on ₹170 book

₹172

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹286

Analyst target

No analyst coverage

—

Blended fair value₹197

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Promoters hold a controlling stake

Bear case

Revenue has been shrinking
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

19.8Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

13.4%Average

Above 15% is considered healthy for Indian equities

ROCE

12.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.37Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹3,849 Cr

P/B

2.26

EPS

₹21.36

Div Yield

0.51%

What changed

Recent changes

Foreign investors-0.6% stake last quarter
Domestic institutions+0.1% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 19.8×

Growth

Shrinking

-2% rev CAGR

Profitability

Healthy

13.4% ROE

Financial health

Comfortable

D/E 0.37

Momentum

N/A

No technicals

Today

Trading activity

Delivery %47.2%

Turnover₹927.13L Cr

Trades7,005

VWAP₹418.18

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-1.9%

+3.5%

10Y

+8.4%

Profit

+5.5%

-7.0%

10Y

+10.9%

EPS

+6.0%

-6.6%

10Y

+11.7%

Profile

Cons

The company has delivered a poor sales growth of 3.55% over past five years.
Tax rate seems low
Company has a low return on equity of 13.3% over last 3 years.
Company might be capitalizing the interest cost
Dividend payout has been low at 6.72% of profits over last 3 years
Promoter holding has decreased over last 3 years: -4.55%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.58 pts; domestic institutions added 0.10 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

55%

Promoter

Promoters

55.0%0.00

Public

33.2%+0.48

FII / FPI

1.6%-0.58

DII

10.2%+0.10

Total shareholders

1,44,946-3,417 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter55.03%

FII1.57%

DII10.22%

Public33.19%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

AARTI DRUGS LTD. valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

AARTI DRUGS LTD. peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare AARTI DRUGS LTD. with peers

AARTI DRUGS LTD. vs SUN PHARMACEUTICAL IND L AARTI DRUGS LTD. vs DIVI S LABORATORIES LTD AARTI DRUGS LTD. vs TORRENT PHARMACEUTICALS L AARTI DRUGS LTD. vs APOLLO HOSPITALS ENTER. L AARTI DRUGS LTD. vs ZYDUS LIFESCIENCES LTD AARTI DRUGS LTD. vs CIPLA LTD

AARTI DRUGS LTD.

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

AARTI DRUGS LTD. valuation & research

AARTI DRUGS LTD. peers in Healthcare

Compare AARTI DRUGS LTD. with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Cons

Ownership breakdown

Ownership over time

Frequently asked questions